Skip to main content

VTGN

Stock
Health Care
Biotechnology

Performance overview

VTGN Price
Price Chart

Forward-looking statistics

Beta
0.77
Risk
68.23%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tubeā„¢, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.

Company info

SectorHealth Care
IndustryBiotechnology
Employees35
Market cap$102.4M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth+4.5
Credit+4.6
Liquidity-1.3
Inflation-0.2
Commodities-1.2
Interest Rates-4.2

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio-1.53
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayFebruary 14, 2025
Next dividend day—
Ex. dividend day—

News

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.22 per share a year ago.

Zacks Investment Research (February 13, 2025)
This overlooked corner of women's health could be a $350 billion market opportunity

Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.

CNBC (March 15, 2024)
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (June 21, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free